MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock in...
$2,500,000
Net cash provided by
(used in) financing...
$2,285,000
(207827.27%↑ Y/Y)
Canceled cashflow
$215,000
Net decrease in cash
and cash...
$1,595,375
(223.71%↑ Y/Y)
Canceled cashflow
$689,625
Payment of offering
costs in connection...
-$215,000
(-19445.45%↓ Y/Y)
Prepaid expenses and
other current assets
-$483,251
(-705.87%↓ Y/Y)
Amortization of internally
developed software
$199,343
(-72.89%↓ Y/Y)
Accounts receivable
-$115,537
(89.04%↑ Y/Y)
Operating lease
right-of-use asset
$15,524
(-46.42%↓ Y/Y)
Depreciation of property and
equipment
$2,123
(-93.80%↓ Y/Y)
Stock-based compensation
expense
$153
(-99.14%↓ Y/Y)
Net cash used in
operating activities
-$689,625
(46.46%↑ Y/Y)
Canceled cashflow
$815,931
Net loss
-$1,362,811
(49.63%↑ Y/Y)
Deferred revenue
-$65,039
(66.93%↑ Y/Y)
Accounts payable
-$35,441
(-130.18%↓ Y/Y)
Accrued expenses
-$24,233
(95.37%↑ Y/Y)
Operating lease liability
-$14,086
(41.99%↑ Y/Y)
Bad debt expense
-$3,946
(-122.45%↓ Y/Y)
Back
Back
Cash Flow
iSpecimen Inc. (ISPC)
iSpecimen Inc. (ISPC)
source: myfinsight.com